30 closest matches · ranked by relevance
Breast Cancer · Invasive Breast Cancer
Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…
Breast Cancer
Primary: Overall Disease Response Rate — 0; 0; 1; 1 Participants
Breast Cancer
Primary: Median Progression Free Survival (PFS) — 7.2 months
Metastatic Beast Cancer
Primary: Progression-free Survival (PFS) Rate at 3 Months — 50.1 percent of participants
Breast Cancer
Primary: Increase of ER Protein Expression in ER-Negative/Low Breast Cancer — 1 participants
Metastatic Breast Cancer
Primary: Response Rate (RR) — 4.8; 0 percentage of participants
Breast Cancer
Primary: Change in Ki-67 in Breast Tissue of High-Risk Women
Malignant Neoplasm of Female Breast
Primary: Overall Response Rate — 25; 21 Participants
Breast Cancer
Primary: Change in Primary Tumor FFNP Uptake Before and After Estradiol Challenge as Measured by Percent Change in Standardized Uptake Value (SUV) — 11.0 percent change in SUV
Breast Cancer
Primary: Pathologic Complete Response — 5; 1; 4; 2 Participants
Breast Neoplasm
Primary: Best Overall Response (BOR) — 20.0; 10.3 percentage of participants — p=0.1109
Estrogen Receptor Negative · HER2/Neu Negative · Progesterone Receptor-negative
Primary: Number of Participants Experiencing a Dose Limiting Toxicity (DLT) (Phase I) and the Recommended Phase IB Dose (RP2D) — 4; 4; 2 Participants
Breast Cancer
Primary: Pathologic Complete Response Rate After Preoperative Therapy With Cisplatin and Bevacizumab in ER-, PR-, Human Epidermal Growth Factor Receptor 2 (HER2) -Negative Early…
Neoplasms
Primary: Progression-free Survival (PFS) - Phase II Part — 7.3; 5.6 Months — p=0.9057
Breast Cancer · Stage II Breast Cancer · Stage III Breast Cancer
Primary: Overall Response Rate as Measured by Clinical Exam, Standard Imaging, and Surgical Pathology Findings — 23; 0 Participants
Breast Neoplasms
Primary: Clinical Benefit Rate (CR Plus PR Plus SD) — 0; 0; 3; 1 participants
Estrogen Receptor-negative Breast Cancer · Progesterone Receptor-negative Breast Cancer · Recurrent Breast Cancer
Primary: Clinical Benefit Rate (CR + PR + SD > 6 Months). — 7.1; 6.3 Percent of Participants
Breast Cancer
Primary: Change From Baseline in Tumor Cell Proliferation, as Measured by the Proportion of Nuclei Staining Ki67-Positive at Surgery Relative to Baseline in Pre- and…
Estrogen Receptor-positive Breast Cancer · Progesterone Receptor Positive Tumor · Recurrent Breast Cancer
Primary: Number of Participants With Grade 4 Toxicity
Breast Neoplasms · Breast Cancer · Estrogen-receptor Positive Breast Cancer
Primary: Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Breast Cancer · Metastasis
Primary: Number of Participants With Objective Response — 0; 1; 1; 1 participants
Breast Neoplasms
Primary: Progression-Free Survival (PFS) — 2.0; 2.7; 1.7; 2.5 Months — p=0.8885
Breast Cancer
Primary: Clinical Benefit Rate — 0.12 proportion of participants
Breast Cancer
Primary: Complete Response Rate — 2; 8 Participants
Breast Cancer
Primary: Mean Percent Positive Proximity Ligation Assays of All Tumor Protein p53-wild Type Breast Tumors in Participants by Treatment Arm — 27.0; 4.4 percentage of positive PLA
Triple Negative Locally Advanced Non-resectable Breast Cancer · Metastatic Breast Cancer
Primary: Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST]) — 30.0; 35.9 percentage of participants
Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Primary: Percentage of Participants With Clinical Benefit at Week 16: Evaluable Population — 33.3 Percentage of participants
Breast Cancer
Primary: Objective Response Rate (ORR) Determined by Clinical Palpation — 58.9; 53.8 percentage of participants
Metastatic Breast Carcinoma · Stage IIIB Breast Cancer AJCC v7 · Stage IIIC Breast Cancer AJCC v7
Primary: Number of Participants With Progression Free Survival (PFS) at 12 Months — 8; 16 Participants
Breast Cancer
Primary: Pathological Response for Basal Group 2 — 16; 14; 5; 11 Participants